Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norma A Palma

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Gastroenterology|April 3, 2026
Response to Letters Regarding "Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma"Aimee L Lucas, Randall E Brand, Norma A Palma
Diagnostics (Basel, Switzerland)|December 30, 2025
Analytical Validation of a Serum Biomarker Signature for Detection of Early-Stage Pancreatic Ductal AdenocarcinomaRobyn Pescatore, Naphtali Milliken, Thomas King, et al.
Journal of Proteome Research|December 19, 2024
Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) Using Multiplex Proteomics TechnologyAlcibiade Athanasiou, Natasha Kureshi, Anja Wittig, et al.
Current Oncology (Toronto, Ont.)|November 26, 2025
Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal AdenocarcinomaPatricio M Polanco, Tamas Gonda, Erkut Borazanci, et al.
Cancers|June 13, 2025
A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk IndividualsNorma A Palma, Aimee L Lucas, Bryson W Katona, et al.
Case Reports in Oncology|November 20, 2014
A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to CrizotinibJon H Chung, Siraj M Ali, Jenni Davis, et al.
Breast Cancer Research and Treatment|October 14, 2015
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterationsJeffrey S Ross, Siraj M Ali, Kai Wang, et al.
Case Reports in Oncology|September 19, 2014
Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown PrimaryNorma A Palma, Siraj M Ali, Jamie O'Connor, et al.
The Oncologist|April 18, 2015
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapiesSiraj M Ali, Eric M Sanford, Samuel J Klempner, et al.
The Oncologist|December 17, 2015
Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic AlterationsSiraj M Ali, Sumanta K Pal, Kai Wang, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Gastroenterology|April 3, 2026
Response to Letters Regarding "Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma"Aimee L Lucas, Randall E Brand, Norma A Palma
Diagnostics (Basel, Switzerland)|December 30, 2025
Analytical Validation of a Serum Biomarker Signature for Detection of Early-Stage Pancreatic Ductal AdenocarcinomaRobyn Pescatore, Naphtali Milliken, Thomas King, et al.
Journal of Proteome Research|December 19, 2024
Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) Using Multiplex Proteomics TechnologyAlcibiade Athanasiou, Natasha Kureshi, Anja Wittig, et al.
Current Oncology (Toronto, Ont.)|November 26, 2025
Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal AdenocarcinomaPatricio M Polanco, Tamas Gonda, Erkut Borazanci, et al.
Cancers|June 13, 2025
A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk IndividualsNorma A Palma, Aimee L Lucas, Bryson W Katona, et al.
Case Reports in Oncology|November 20, 2014
A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to CrizotinibJon H Chung, Siraj M Ali, Jenni Davis, et al.
Breast Cancer Research and Treatment|October 14, 2015
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterationsJeffrey S Ross, Siraj M Ali, Kai Wang, et al.
Case Reports in Oncology|September 19, 2014
Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown PrimaryNorma A Palma, Siraj M Ali, Jamie O'Connor, et al.
The Oncologist|April 18, 2015
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapiesSiraj M Ali, Eric M Sanford, Samuel J Klempner, et al.
The Oncologist|December 17, 2015
Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic AlterationsSiraj M Ali, Sumanta K Pal, Kai Wang, et al.
Pageof 2